1. Home
  2. FERG vs ARGX Comparison

FERG vs ARGX Comparison

Compare FERG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferguson plc

FERG

Ferguson plc

HOLD

Current Price

$225.67

Market Cap

49.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$838.20

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FERG
ARGX
Founded
1887
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Miscellaneous
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.8B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FERG
ARGX
Price
$225.67
$838.20
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$250.07
$971.89
AVG Volume (30 Days)
1.5M
301.6K
Earning Date
12-09-2025
10-30-2025
Dividend Yield
1.57%
N/A
EPS Growth
18.63
N/A
EPS
9.88
23.27
Revenue
$31,159,000,000.00
$3,683,281,000.00
Revenue This Year
$7.73
$91.44
Revenue Next Year
$5.21
$36.90
P/E Ratio
$22.99
$33.60
Revenue Growth
4.92
92.98
52 Week Low
$146.00
$510.06
52 Week High
$256.93
$934.62

Technical Indicators

Market Signals
Indicator
FERG
ARGX
Relative Strength Index (RSI) 38.13 36.60
Support Level $225.73 $843.03
Resistance Level $229.24 $858.80
Average True Range (ATR) 4.37 14.16
MACD -0.11 -5.19
Stochastic Oscillator 33.77 14.10

Price Performance

Historical Comparison
FERG
ARGX

About FERG Ferguson plc

Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: